MITOMYCIN - 10 YEARS AFTER APPROVAL FOR MARKETING

被引：107

作者：

DOLL, DC

WEISS, RB

ISSELL, BF

机构：

[1] WALTER REED ARMY MED CTR,MED ONCOL SECT,WASHINGTON,DC 20012

[2] UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814

[3] BRISTOL MYERS CO LABS,SYRACUSE,NY 13201

[4] SUNY UPSTATE MED CTR,SYRACUSE,NY 13210

来源：

关键词：

D O I：

10.1200/JCO.1985.3.2.276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：276 / 286

页数：11

共 147 条

[1] AISNER J, 1981, CANCER TREAT REP, V65, P979
[2] ARGENTA LC, 1983, CANCER, V51, P1080, DOI 10.1002/1097-0142(19830315)51:6<1080::AID-CNCR2820510618>3.0.CO
[3] 2-Y
[4] BAKER L H, 1976, Medical and Pediatric Oncology, V2, P207, DOI 10.1002/mpo.2950020211
[5] BAKER LH, 1979, MITOMYCIN C CURRENT, P77
[6] MITOMYCIN-C AND HIGH-DOSE MEDROXYPROGESTERONE ACETATE IN THE TREATMENT OF METASTATIC BREAST-CANCER - RESULTS OF A PHASE-II-STUDY OF THE AIO
BARTSCH, HH
BLOSSEY, HC
NAGEL, GA
[J]. ONKOLOGIE, 1982, 5 (05): : 249 - &
[7] BITRAN JD, 1979, CANCER TREAT REP, V63, P2049
[8] BRACKEN RB, 1980, UROLOGY, V16, P11
[9] BRADNER WT, 1968, CANCER CHEMOTH REP, V52, P389
[10] BRUCKNER HW, 1979, CANCER TREAT REP, V63, P395